Competing interests
ONCOLOGY, EMD
A.M.M. – Grants/Contracts: Incyte, Merck, Genentech, BMS, Transgene, EMD Serono, Trisalus. Consulting Fees: Atheneum, First Thought, Opinion Site, Alcimed. Honoraria: ANCO, ACVR. Advisory Board and Stock Options: Multiplex Thera. M.E.D.—Grants/Contracts: Merck, Genentech, EMD Serono. Consulting Fees: Astra Zeneca. Honoraria: Curio, Dava. G.L.—none. E.M.—none. A.A.M.—none. A.I.M.—none. A.B.—none. A.M.—none. S.L.S.— none. L.B.—none. S.C.—none. D.E.—none. T.L.—none. L.V.V.—none. H.M.M.—Consulting fees: RefleXion. F.L.—none. L.G.—none. L.A.M.—none. R.J.C.—Advisory Board: NAKI Therapeutics. J.W.R.—Grants/Contracts: AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Revolution Medicines, Spectrum. K.A.S.—Grants/Contracts: Navigate Biopharma, Tesaro/GSK, Moderna Inc., Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Eli Lilly, Boehringer-Ingelheim and Akoya Biosciences. Consulting Fees: Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, EMD Serono, Takeda, Torque/Repertoire Therapeutics, Agenus, Genmab, OnCusp, Parthenon Therapeutics, Bristol-Myers Squibb, Roche, CDR life, Sensei Therapeutics, Molecular Templates and Merck. Honoraria: Takeda, Fluidigm, Merck, Brstil Myers Squibb, PeerView, Forefront collaborative. W.J.M.—Grants/Contracts: Merck. K.K.—Grants/Contracts: Genentech, BMS, Transgene. Advisory Board: Genentech. Other: IASLC. A.M.M., M.E.D., and K.K. received support from Genentech in the form of providing Atezolizumab for this clinical trial. Genentech stand to potentially benefit financially from this report. Genentech played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the paper.